my father has drank whiskey for the last 40 years they now say he has alachol hepititas what can be done for h

Question

he remarried after signing papers at the social secerty office saying he was mentally inept to sign anwthing at all... he went to another state to get married. I need to know what to do if something happens to him?

Answer 1

His Liver is dead...all that booze has pickled it!

Answer 2

Alcoholic hepatitis is an inflammation of the liver caused by alcohol.



Definition

Alcoholic hepatitis is an inflammation of the liver caused by alcohol.

Description

Irritation, be it from toxins or infections, causes a similar response in body organs. The response is known as inflammation and consists of:


an increase in the blood to the affected organ


redness and swelling of the organ


influx of immune agents like white blood cells and their arsenal of chemical weapons


pain

As the acute process subsides, there is either healing or lingering activity. Lingering activity--chronic disease--has a milder presentation with similar ingredients. Healing often takes the form of scarring, wherein normal functioning tissue is replaced by tough, fibrous, and non-productive scar. Both chronic disease and healing can happen simultaneously, so that scar tissue progressively replaces normal tissue. This leads to cirrhosis, a liver so scarred it is unable to do its job adequately.

Alcohol can cause either an acute or a chronic disease in the liver. The acute disease can be severe, even fatal, and can bring with it hemolysis--blood cell destruction. Alcohol can also cause a third type of liver disease--fatty liver, in which the continuous action of alcohol turns the liver to useless fat. This condition eventually progresses to cirrhosis if the poisoning continues.

Causes and symptoms

Inflammation of the liver can be caused by a great variety of agents--poisons, drugs, viruses, bacteria, protozoa, and even larger organisms like worms. Alcohol is a poison if taken in more than modest amounts. It favors destroying stomach lining, liver, heart muscle, and brain tissue. The liver is a primary target because alcohol travels to the liver after leaving the intestines. Those who drink enough to get alcohol poisoning have a tendency to be undernourished, since alcohol provides ample calories but little nutrition. It is suspected that both the alcohol and the poor nutrition produce alcoholic hepatitis.

Diagnosis

Hepatitis of all kinds causes notable discomfort, loss of appetite, nausea, pain in the liver, and usually jaundice (turning yellow). Blood test abnormalities are unmistakably those of hepatitis, but selecting from so many the precise cause may take additional diagnostic work.

Treatment

As with all poisonings, removal of the offending agent is primary. There is no specific treatment for alcohol poisoning. General supportive measures must see the patient through until the liver has healed by itself. In the case of fulminant (sudden and severe) disease, the liver may be completely destroyed and have to be replaced by a transplant.

Prognosis

The liver is robust. It can heal without scarring after one or a few episodes of hepatitis that resolve without lingering. It can, moreover, regrow from a fragment of its former self, provided there is not disease or poison still inhibiting it.

Prevention

Alcohol is lethal in many ways when ingested in excess. Research suggests that the maximum healthy dose of alcohol per day is roughly one pure ounce--the amount in two cocktails, two glasses of wine, or two beers.

Answer 3

Forget anything you have ever been told about Diabetes.

And get this - it has nothing to do with insulin, exercise, diet or anything else you've heard in the past. It's all based on latest breakthrough research that Big Pharma is going Stir Crazy to hide from you.

Visit here : https://tr.im/5DNNl to find out what all the fuss is about.

Answer 4

when they find out that is it for him there is nothing much u can do for him.

Answer 5

another whisky,,the damage is done now....

Answer 6

Alcohol and Hepatitis C

Kamran Safdar, M.D.; Eugene R. Schiff, M.D.

Semin Liver Dis 24(3):305-315, 2004. © 2004 Thieme Medical Publishers
Posted 11/02/2004

Abstract and Introduction
Abstract

Alcohol abuse and hepatitis C virus (HCV) infection coexist with chronic liver disease in many patients. The mechanism of injury in these patients is probably multifactorial and involves, but is not limited to, a combination of diminished immune clearance of HCV, oxidative stress, emergence of HCV quasi-species, hepatic steatosis, increased iron stores, and increased rate of hepatocyte apoptosis. In patients with HCV infection, alcohol consumption is known to cause accelerated progression of liver fibrosis, higher frequency of cirrhosis, and increased incidence of hepatocellular carcinoma (HCC). These patients also have decreased survival as compared with patients with either alcohol abuse or HCV liver injury alone. Alcohol abuse causes decreased response to interferon treatment in HCV patients. It is therefore necessary for patients with HCV infection to abstain from alcohol consumption.
Introduction

Chronic hepatitis C infection and alcohol abuse account for 70 to 90% of all the cases of chronic liver diseases in the western world. About 20% of chronic alcoholics and patients with hepatitis C infection develop cirrhosis over a period of 20 to 30 years[1,2] and a portion of these patients develop HCC.[3] Hepatitis C-related cirrhosis now accounts for more than 50% of all liver transplants performed in the United States.[4]

The progression to cirrhosis in patients with chronic hepatitis C is affected by several variables. Published data show that viral genotype and viral load, although important predictors of response to treatment with interferon,[5] lack association with disease severity.[6] Besides the genetic factors in the host,[7] there are three other independent variables associated with disease progression in patients infected with hepatitis C. These are age at infection > 40 years, heavy ethanol abuse > 50 g/d, and male gender.[8-10]


Epidemiology

Several studies have shown a high prevalence of anti-HCV using first-generation immunosorbent assay among alcoholic patients with liver disease.[11-15] Testing with recombinant immunoblot assays has shown that 8 to 43% of alcoholic patients with liver disease have anti-HCV. Most alcoholics with anti-HCV and liver disease also have HCV RNA (4 to 84%).[16-19] HCV RNA is detected in some alcoholic patients with liver disease who are anti-HCV negative.[20]

There is no clear-cut explanation for increased prevalence of hepatitis C infection in alcoholics. Some studies have suggested that the increased prevalence of anti-HCV in alcoholics is primarily due to a past history of intravenous drug use (IVDU).[21-23] However, others have shown that there was no significant difference between the prevalence of anti-HCV in alcoholics with and without risk factors (IVDU and blood transfusion) for contracting HCV.[24,25]

Epidemiological studies also show a difference in the severity of HCV and alcoholism along gender and racial or ethnic lines. Socioeconomic status is a known risk factor for HCV and is probably a factor among alcoholic patients. African Americans and Hispanics have a higher prevalence of alcohol abuse and HCV.[26] In addition, African Americans have a higher prevalence of genotype 1b HCV and poor response to interferon treatment.[27] Furthermore, HCV is less common in women than in men, and the liver disease is milder and responds better to interferon treatment than in men. On the other hand, women who consume alcohol are more prone to develop liver disease and cirrhosis with relatively lower amounts of alcohol consumption.[28-31]
Effect of Alcohol on Liver Fibrosis Progression

Over the past decade, several studies have shown that alcohol increases the progression of HCV to cirrhosis and HCC. Seef et al[32] reported that more than two thirds of deaths with end-stage liver disease secondary to non-A, non-B hepatitis occurred in alcoholic patients. The threshold level above which alcohol potentiates the progression of HCV disease is unknown. Approximately 10 g of alcohol is contained in 12 oz of regular beer, 5 oz of wine, or 1 oz of distilled spirits (80 proof). Excessive alcohol intake thought to potentiate the progression of chronic hepatitis C has been reported to be between 30 and 80 g/d in different studies. It has been shown that alcohol abuse accelerated the progression of hepatic injury in patients with HCV.[33-42] In 1997, Poynard et al showed that in patients with HCV who drank more than 50 g of alcohol per day there was a 34% increased rate of fibrosis as compared with those who drank less. In one study in which HCV was contracted via IVDU, it was noted that the relative risk of end-stage liver disease was 3.6 for persons drinking > 37 g/d and 1.57 for those drinking 13 to 37 g/d.[37] In another study in which risk of developing HCV cirrhosis was evaluated after blood transfusions, it was found that the risk of cirrhosis was fourfold higher in those who drank > 80 g/d.[38]

Unlike the case of heavy alcohol abuse, the effect of moderate amount of drinking and the progression of fibrosis in patients with HCV infection is not yet fully understood.[43] However a recent prospective study from France shows that both histological activity and fibrosis gradually increase with the amount of alcohol use and that even moderate alcohol consumption, as low as 31 to 50 g/d in men and 21 to 50 g/d in women, accelerates the histological lesions in chronic HCV patients.[44] In another retrospective study from Sweden, the effect of moderate alcohol consumption (< 40 g/d) on liver fibrosis progression in patients with HCV was analyzed.[45] Documented histological progression of liver disease was most likely among those who consumed a greater amount of alcohol (5.7 g/d) and had a higher drinking frequency (drinking days per year) of 34.5 as compared with those who drank less (2.6 g/d) and had a lower drinking frequency of 8.2.

Two studies from France have shown the impact of drinking on liver fibrosis progression in patients who are coinfected with HIV and HCV.[46,47] Drinking more than 50 to 80 g/d was associated with increased fibrosis progression and the risk of death from cirrhosis.

Most epidemiological studies have shown that the effects of alcohol and hepatitis C on liver disease progression are synergistic.[48-51] Corrao and Arico[36] demonstrated that the relative risk for developing cirrhosis in alcohol abusers not infected with HCV was 15 as compared with 9 in HCV-infected patients who did not drink. However, the risk in HCV-infected alcohol abusers was 147. In addition, the interaction between lifetime daily alcohol intake (LDAI) and HCV was additive at < 50 g/d and synergistic for > 50 g/d. However, one study showed that the effects of alcohol and HCV on cirrhosis were additive and not synergistic.[52]
Pathogenesis of Liver Injury

The mechanisms of advanced liver injury induced by coexisting alcohol and HCV are not fully understood. Various proposed mechanisms include immune dysfunction, increased viral replication, emergence of HCV quasi-species, apoptosis, steatosis, and hepatic iron overload. The typical histological pattern of liver injury in liver biopsies from alcoholic and HCV-infected patients is similar to that in nonalcoholic patients with chronic HCV.[21,52] Liver biopsy specimens from one study[53] showed that in 46 alcoholic patients with HCV RNA positivity lymphoid follicles were present in 34.7% and lymphoid aggregates in 93.3% of the portal tracts. These findings suggest that the hepatic injury in most alcoholics with HCV is due to hepatitis C infection rather than to alcoholic injury.

Alcohol, HCV, and Immunology. Acute alcohol ingestion results in generalized immunosuppression of the immune system.[54,55] It has also been suggested that alcohol abuse causes functional impairment of granulocytes, lymphocytes, and macrophages.[56-58] Plasma levels of proinflammatory cytokines tumor necrosis factor alpha (TNF-α), interleukin (IL)-6, and IL-8 are increased markedly in acute alcoholic hepatitis and correlate with disease severity.[59] Szabo et al[60] reported that alcohol causes decreased antigen-specific T cell proliferation because of impaired monocyte accessory function in association with raised concentrations of IL-10 and IL-13 and decreased concentrations of interferon-gamma (IFN-γ). These effects in chronic HCV patients, unlike those seen in acute HCV infection, in whom there is a T helper (Th) 1 response, may in part result from a Th2 response that could explain a decrease in the clearance of the virus by the host.[61] One study in mice showed that ethanol-fed mice have inhibition of Th and cytotoxic T-lymphocyte (CTL) responses to HCV core protein and reduced expression of cytokines.[62] On the other hand, several studies have shown that alcohol abuse is associated with increased numbers of activated lymphocytes in the blood even without liver disease.[63,64] There have been a few animal studies that showed that, in the presence of infection, alcohol consumption causes an enhanced inflammatory response in the liver.[65-67] Therefore, the immunosuppressive effect of alcohol probably impairs the clearance of HCV, and viral persistence results in an increased nonspecificinflammatory response. This response, consisting of macrophages and lymphocytes and proinflammatory cytokines, causes nonspecific liver damage. It has been shown that the most important immune response to HCV infection is the production of CD8+ CTLs.[68-70] These cells produce IFN-γ, which inhibits the HCV virus from replication and also noncytolytically clears it from the infected cells.[71]

Although alcohol causes immunosuppression, this suppression is probably not complete. The antigen-specific CTLs that are produced in response to HCV infection migrate to the liver, where they cause apoptosis of infected hepatocytes via interaction of Fas ligand expressed on activated CTL and Fas on hepatocytes.[72,73] This action may be enhanced by alcohol[74] and other proinflammatory cytokines (TNF-α) produced by CTLs.[75] In addition, hepatocyte destruction by CTL is also influenced by perforin and granzyme-mediated mechanisms.[76] Finally, alcohol causes sensitization of hepatocytes to the immune-mediated response directed at the virus, either through metabolites of alcohol-like acetaldehyde or secondary to oxidative stress.[77]

Therefore, in patients with alcohol and HCV, immunosuppression by alcohol further compromises HCV clearance. The persistence of HCV continues to fuel the interactions between lymphocytes and hepatocytes that in turn lead to chronicity of HCV infection with all its sequelae.

Alcohol, HCV, and Oxidative Stress. Oxidative stress is noted to be high both in patients with HCV[78-83] and in those who are alcoholics.[84-88] An increase in the formation of mitochondrial reactive oxygen species (ROS) has been reported as a cause of alcohol-induced oxidative stress.[89] Ethanol consumption also increases the formation of ROS by cytochrome P450-2E1, which enhances lipid peroxidation in both mice[90] and humans.[91] HCV core protein also causes oxidative damage[92-94] by triggering the release of increased mitochondrial ROS in association with cytochrome c. One recent study showed that the added effects of ethanol and HCV act synergistically to increase hepatic free radical formation and alteration of liver antioxidant defenses.[95] The same study reports that both moderate alcohol consumption (< 50 g/d) and heavy ethanol use (> 50 g/d) increases the risk of developing oxidative stress 3-fold and 13-to 24-fold, respectively. It also was noted that among alcoholic HCV-positive patients, diffuse piecemeal necrosis was four times more frequent in those patients with lipid peroxidation antibodies than it was in those without these antibodies.

Another study indicated that ethanol consumption and HCV additively increase hepatic lipid peroxidation.[96] Perlemuter et al[96] also showed a synergistic effect of alcohol and HCV on hepatic transforming growth factor beta (TGF-β) and TNF-α expression. TGF-β activates hepatic stellate cells (HSC) and stimulates production of more TGF-β, which is a stimulus for overproduction of extracellular matrix. Increased expression of TNF-α causes increased formation of ROS, which in turn may increase the hepatic fibrosis. Reactive lipid peroxidation products also cause somatic mutations and chromosomal alterations.[97,98] Moreover, oxidative stress activates nuclear transcription factor-kappa β (NF-κβ),[99] which plays a role in hepatic inflammation, liver injury and regeneration, and HCC.[100-102] In addition, ethanol and HCV core protein cause activation of NF-κβ in hepatic cells.[103,104]

Alcohol, Anti-HCV, and HCV RNA. There are several studies that show that alcoholic patients with anti-HCV have more severe liver damage than do antibody-negative patients.[19,20,105-109] There are conflicting reports about the effects of alcohol on serum HCV RNA. Some have suggested that chronic ethanol consumption leads to a higher viral load,[8,18-20,35,110] whereas others have not found a relationship between HCV RNA and the amount of drinking.[30,34,52,111,112] A study from Japan showed that patients with alcoholic cirrhosis and HCV RNA had higher alanine aminotransferase levels and histological indices of severe liver disease than did those without HCV RNA.[20] In another study from Japan[19] among patients with alcoholic liver disease, HCV RNA detection was highest in those with chronic hepatitis (84%) and HCC (100%). An association between HCV RNA level and degree of hepatic damage was shown by Fanning et al,[113] but others have not confirmed it.[114,115] Two studies have tried to find a correlation between intrahepatic HCV RNA and level of alcohol consumption. One study found a relationship between daily ethanol use and intrahepatic HCV RNA but did not find a correlation between levels of intrahepatic HCV RNA and degree of hepatic injury.[116] The other study found that alcohol abuse did not alter intrahepatic HCV RNA.[117] A reduction in intake of ethanol has been shown by some,[18,111,118] but not by others,[112,117]to cause a decrease in serum HCV RNA. Last, alcohol may potentiate the HCV replicon expression via activation of NF-κβ and the endogenous opioid system.[119]

Alcohol and HCV Quasi-Species. Two studies have shown the effect of alcohol on HCV quasi-species. One study has shown that HCV quasi-species complexity increased in patients with alcoholic liver disease.[120] Another study has suggested that alcoholics have increased quasi-species complexity in hypervariable region 1 of HCV.[121] Alcohol immunosuppression probably promotes the accumulation of multiple variants (quasi-species), which in turn causes viral escape from the immune onslaught.

Hepatic Iron Overload. Hepatic iron concentrations were found to be significantly higher in HCV-positive patients with a history of alcohol abuse as compared with nonabusers.[122,123] Because increased hepatic iron stores enhances HCV disease progression,[124] the superimposed alcohol-induced iron deposition is likely to promote further hepatic fibrosis.

Hepatocyte Apoptosis. As stated earlier, hepatocyte apoptosis occurs more frequently in HCV infections than in normal controls and is further enhanced by active ethanol consumption.[74] Binding of Fas ligand on CTLs to Fas receptor on hepatocytes results in caspase 8 activation, causing mitochondrial dysfunction that leads to cell death.[125] A recent study indicated a higher rate of hepatocyte apoptosis and absent bcl-2 (inhibitor of apoptosis) expression in HCV patients who consumed more than 30 g/d of ethanol.[126] In contrast, patients who drank smaller amounts of alcohol had lower rates of apoptosis and more frequent expression of bcl-2. It has also been shown that cells expressing HCV core protein were sensitized to TNF-α-induced apoptosis.[127]

Hepatic Steatosis. Steatosis is a common histological finding in patients with HCV.[128-132] Comorbidity with nonalcoholic steatosis or viral-induced steatosis as observed with HCV genotype 3 is often present. In some cases, alcohol has been identified as an independent risk factor in the pathogenesis of HCV-associated steatosis.[133] Alcohol-induced steatohepatitis potentiates liver fibrosis in HCV-infected patients.[134,135] In a recent study of patients with chronic HCV infection, extensive fibrosis or cirrhosis occurred in those with moderate or severe steatosis independent of alcohol intake as well as in those with piecemeal necrosis.[136] The median progression rate of fibrosis was twice as high among drinkers with steatosis than it was among drinkers without steatosis or nondrinkers with or without steatosis.

Alcohol and HIV/HCV Coinfection. Patients coinfected with HIV and HCV have increased rates of liver fibrosis.[46,47] Most coinfected patients have a past history of either IVDU or significant ethanol abuse. It has been suggested that coinfected patients who drank ethanol are more likely to die of end-stage liver disease.[137] Another study showed that coinfected patients who drank ethanol had a higher incidence of cirrhosis than did HCV-positive alcoholic patients who were HIV negative.[138]
Alcohol, Hepatitis C, Cirrhosis, and Survival

All of these studies cited make it abundantly clear that alcoholic and HCV-positive patients have demonstrable increased rates of progressive hepatitis and fibrosis, as compared with appropriate controls. The "Dionysos" study showed that alcoholics who drank more than 30 g/d of ethanol for more than 10 years had a threefold higher incidence for development of cirrhosis in both HCV-negative and -positive patients.[30] However, HCV-positive patients who drank more than 30 g/d had a 32% higher risk of developing cirrhosis as compared with those who drank less than 30 g/d. In their study, Harris et al[139] proved that patients with HCV who drank more than 30 g/d of alcohol had an increased risk of fibrosis and a lower survival rate than did with those who drank less than 30 g/d. One report suggested a twofold to threefold increased risk of liver cirrhosis and decompensated liver disease in patients with HCV and a history of heavy alcohol abuse (women > 40 g/d, men > 60 g/d) for more than 5 years.[34] By the second decade, 58% were cirrhotic, compared with 10% in alcohol-free patients. Another study in patients with HCV and alcohol excess demonstrated that patients who developed cirrhosis had a greater total and daily lifetime alcohol use.[10] The odds ratio was 1.16/100,000 g of ethanol consumed during life. Cirrhotic patients were also older both at the time of study and at the time of infection and had a longer duration of infection than did those who did not have cirrhosis.

In a study by Niederau et al,[39] 838 HCV patients were followed for a period of 50 ± 27 months. During that time, survival was decreased by the presence of four factors: (1) cirrhosis, (2) long disease duration, (3) history of IVDU, and (4) excessive alcohol consumption. In patients who consumed > 80 g/d of ethanol, the risk ratio for death, liver transplantation, and clinical complications of liver disease was 2.3. A recent analysis showed a higher risk of death with an odds ratio of 1.14 in patients with HCV and alcohol abuse.[140] Patients were also younger at the time of hospitalization and had a higher death rate compared with those who had either HCV or alcoholic liver disease alone.
Alcohol, HCV, and HCC

Alcoholic liver disease and HCV infection are both considered as risk factors for the development of HCC. The prevalence of anti-HCV in alcoholics with HCC range from 35 to 85%;[17,141-143] one Japanese study revealed that 100% of alcoholics with HCC were positive for HCV RNA.[19] Several authors have shown that the probability of developing HCC was significantly higher in alcoholics who were anti-HCV positive in contrast to those who were anti-HCV negative.[24,144,145] There is an increased incidence of HCC in patients with HCV and alcoholic liver disease.[50,51,146-156] Most of these studies have shown alcohol to be an independent risk factor for HCC in HCV-positive patients. In one study there was a 1.5- to 2.5-fold increased risk of cirrhosis and HCC in HCV-infected patients who consumed > 80 g/d of alcohol.[50] A later study found that HCV-infected patients who drank ethanol heavily had a twofold greater risk of developing HCC than did those who were abstinent or light drinkers.[51]

The time for the development of HCC was shorter in HCV-infected patients who drank alcohol excessively than it was for those who did not drink. Among HCV-positive patients who drank more than 46 g/d of ethanol, HCC developed in an average of 26 ± 6 years as compared with 31 ± 9 years for those who consumed less than 46 g/d.[154] The risk of HCC in HCV-infected patients with alcohol abuse was 8.3 times higher than it was in HCV-negative alcoholic patients. Heavy alcohol abuse results in the development of HCC at a younger age in HCV-infected patients.[157]

The cumulative ratio of HCC in alcoholic cirrhosis without hepatitis B surface antigen or anti-HCV was 7 and 15% versus 20 and 50% in those with hepatitis B surface antigen or anti-HCV-positive patients at the end of the 5th and 10th year, respectively.[158] Kubo et al[159] showed that in HCC patients with HCV and heavy ethanol abuse, the tumors were more anaplastic, with increased capsular, extracapsular, and portal vein invasion as well as intrahepatic metastasis. The survival time was shortened in these patients too. Heavy ethanol use also affected the long-term results of resection of HCV-related HCC. One study from Japan found the median disease-free survival time after HCC resection was 12.6 months in patients with HCV who consumed > 80 g/d of alcohol as compared with 25.4 months in patients who consumed < 80 g/d.[160] The exact mechanisms that promote the development of HCC in patients with HCV and alcohol are clearly not known.[161] Putative mechanisms include accelerated progression of fibrosis, oxidative stress, and potentiation of NF-κβ activation by alcohol and HCV core protein. The binding of acetaldehyde to DNA, impaired DNA repair, activation of environmental precarcinogens, and dietary deficiencies have also been implicated in the pathogenesis of HCC in alcoholic liver cirrhosis.[162]
Effect of Alcohol on Interferon Treatment for HCV

Continued alcohol consumption has been shown to decrease the response to interferon in patients with HCV infection.[163-165] Alcohol negatively influences the IFN-based therapy for HCV by decreasing the compliance to treatment regimen and adversely affecting antiviral actions of IFN. Concurrent alcohol use has been considered as a contraindication during the treatment for HCV. Preferably, the patient should be abstinent for at least 6 to 12 months before initiation of treatment with interferon. Studies from Japan showed that patients with HCV infection and heavy ethanol abuse had the highest levels of HCV RNA,[18] lower efficacy of IFN,[166] and partial benefit from abstinence before treatment initiation.[167] During IFN treatment, HCV RNA clearance is related to cumulative alcohol consumption and HCV RNA levels.[168] In this study, 56% of the patients discontinued ethanol for at least 1 month before the initiation of IFN treatment.

Loguercio et al[110] showed that there was a direct relationship between alcohol use (< 40 g/d or > 80 g/d) and response to IFN treatment. They found that the number of sustained responders decreased as alcohol consumption increased.

An Italian study examined the effects of IFN treatment in HCV-positive patients whose alanine aminotransferase levels remained twice the upper limit of normal despite 6 months of complete alcohol abstinence.[169] The relapse rate was higher in patients with a prior history of mild or heavy ethanol use, than it was for nondrinkers (52, 59, and 36%, respectively). The sustained virological response was 33% in nondrinkers, 20% in mild drinkers, and 9% in those who drank heavily. Age, previous alcohol intake, and genotype 1 were found to be independent predictors of nonresponse to IFN treatment. Six months of alcohol cessation before initiation of IFN treatment seems insufficient to negate the negative influence of lifetime daily intake of alcohol. Several proposed mechanisms of decreased responsiveness to IFN treatment in alcoholics include, but are not limited to, impaired cellular immunity, high HCV RNA levels, lipid peroxidation products, emergence of quasi-species,[170,171] and increased hepatic iron stores.[122,172-174] However, few data exist regarding the effect of alcohol on the combined use of IFN and ribavirin.[175]


Conclusion

Excess alcohol consumption accelerates the progression of chronic hepatitis C toward increased fibrosis, cirrhosis, and HCC. Furthermore, alcoholism compromises the success of antiviral therapy in hepatitis C. Although the prudent approach in most patients with chronic hepatitis C is to avoid alcohol altogether, among those with mild hepatitis C who are not on antiviral therapy 10 g/d among women and 10 to 20 g/d among men is unlikely to adversely affect the natural history and ultimate treatment of the disease and may have beneficial effects for the risk of myocardial infarction.
CE Information

The print version of this article was orginally certified for CME credit. For accreditation details, please contact the publisher, Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001

References

1. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36(Suppl 5):S35-S46
2. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466
3. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis c virus. Hepatology 1990;12:671-675
4. National Institute of Health Management of hepatitis C: 2002. National Institute of Health Consensus Development Conference Statement. Available at: http://consensus.nih.gov/cons/116/Hepc091202.pdf, Accessed September 28, 2002
5. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis c virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-1432
6. Romeo R, Colombo M, Rumi M, et al. Lack of association between type of hepatitis c virus, serum load and severity of liver disease. J Viral Hepat 1996;3:183-190
7. Powell EE, Edwards-Smith CJ, Hay JL, et al. Host genetic factors influence progression in chronic hepatitis C. Hepatology 2000;31:828-833
8. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, DOSVIRC Groups. Lancet 1997;349:825-832
9. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis c virus related liver disease. A French survey of 6664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 1997;26:485-490
10. Ostapowicz G, Watson KJR, Ocarnini SA, et al. Role of alcohol in the progression of liver disease caused by hepatitis virus infection. Hepatology 1998;27:1730-1735
11. Koff RS, Dienstag JL. Extrahepatic manifestations of hepatitis C and the association with alcoholic liver disease. Semin Liver Dis 1995;15:101-109
12. Befrits R, Hedman M, Blomquist L, et al. Chronic hepatitis C in alcoholic patients: prevalence, genotypes and correlation to liver disease. Scand J Gastroenterol 1995;30:1113-1118
13. Mendenhall CL, Moritz T, Rouster S, et al. Epidemiology of hepatitis C among veterans with alcoholic liver disease. Am J Gastroenterol 1993;88:1022-1026
14. Coelho-Little ME, Jeffers LJ, Bernstein DE, et al. Hepatitis C virus in alcohol patients with and without clinically apparent liver disease. Alcohol Clin Exp Res 1995;19:1173-1176
15. Caldwell SH, Li X, Rourk RM, et al. Hepatitis C infection by polymerase chain reaction in alcoholics: false positive ELISA results and the influence of infection on a clinical prognostic score. Am J Gastroenterol 1993;88:1016-1021
16. Nalpas B, Thiers V, Pol S, et al. HCV infection in alcoholics. Gastroenterology 1993;28(Suppl 5):88-90
17. Zarski JP, Thelu MA, Moulin C, et al. Interest of the detection of hepatitis c Virus RNA in patients with alcoholic liver disease. Comparison with the HBV status. J Hepatol 1993;17:10-14
18. Oshita M, Hyashi N, Kasahara A, et al. Increased serum hepatitis c virus RNA Among alcoholic patients with chronic hepatitis C. Hepatology 1994;20:1115-1120
19. Sata M, Fukuizumi K, Uchimura Y, et al. Hepatitis C virus infection in patients With clinically diagnosed alcoholic liver diseases. J Viral Hepat 1996;3:143-148
20. Nishiguchi S, Kuroki T, Yabusako T, et al. Detection of hepatitis c virus Antibodies and hepatitis C virus RNA in patients with alcoholic liver disease. Hepatology 1991;14: 985-989
21. Jiang JJ, Dubois F, Driss F, et al. Clinical impact of drug addiction in alcoholics. Alcohol Alcohol 1995;30:55-60
22. Nalpas B, Thiers V, Pol S, et al. Hepatitis C viremia and anti-HCV antibodies in alcoholics. J Hepatol 1992;14:381-384
23. Verbaan H, Andersson K, Eriksson S. Intravenous drug abuse— the major route of hepatitis C virus transmission among alcohol dependent individuals? Scand J Gastroenterol 1993;28:714-718
24. Brillanti S, Masci C, Siringo S, et al. Serological and histological aspects of hepatitis C virus infection in alcoholic patients. J Hepatol 1991;13:347-350
25. Caldwell SH, Jeffers LJ, Ditomaso A, et al. Antibody to hepatitis C is common among patients with alcoholic liver disease with and without risk factors. Am J Gastroenterol 1991;86:1219-1223
26. Centers for Disease Control Hepatitis C. Epidemiology. Available at: http://CDCGov/ncidod/diseases/hepatitisc/training (CDC website)
27. Howell C, Jeffers LJ, Hoofnagle JH. Hepatitis C in African Americans: summary of a workshop. Gastroenterology 2000; 119:1385-1396
28. Pares A, Caballeria J, Bruguera M, Torres M, Rodes J. Histological course of Alcoholic hepatitis: influence of abstinence, sex and extent of hepatic damage. J Hepatol 1986;2:33-42
29. Becker U, Deis A, Sorensen RT, et al. Prediction of risk of liver disease by alcohol intake, sex and age: a prospective population study. Hepatology 1996;26:1025-1028
30. Bellentani S, Pozzato G, Saccoccio G, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 1999;44:874-880
31. Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997;41:845-850
32. Seef LB, Buskell-Bales Z, Wright EC, et al. Long term mortality after transfusion associated non-A, non-B hepatitis. N Engl J Med 1992;327:1906-1911
33. Serfaty L, Chazouilleres O, Poujo-Rober A, et al. Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: results of a case control study. Hepatology 1997; 26:776-779
34. Wiley TE, McCarthy M, Breidi L, et al. Impact of alcohol on the histologic and clinical progression of hepatitis C infection. Hepatology 1998;28:805-809
35. Pessione F, Degos F, Marcellin P, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histologic lesions in chronic hepatitis C. Hepatology 1998;27:1717-1722
36. Corrao G, Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 1998;27:914-919
37. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral and environmental factors. JAMA 2000;284:450-456
38. Harris DR, Gonin R, Alter HJ, et al. The relationship of acute transfusion associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med 2001;134:120-124
39. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28:1687-1695
40. Pol S, Fontaine H, Carnot F, et al. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients. J Hepatol 1998;29:12-19
41. Shev S, Dhillon AP, Lindh M, et al. The importance of cofactors in the histologic progression of minimal and mild chronic hepatitis C. Liver 1997;17:215-223
42. Shiomi S, Kuroki T, Minamitani S, et al. Effect of drinking on outcome of cirrhosis in patients with hepatitis B or C. J Gastroenterol Hepatol 1992;7:274-276
43. Sachithanandan S, Kay E, Leader M, et al. The effect of light drinking on HCV liver disease: the jury is still out. Biomed Pharmacother 1997;51:295-297
44. Hezode C, Lonjon I, Roudot-Thoraval F, et al. Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C and specific influence of steatosis: a prospective study. Aliment Pharmacol Ther 2003;17:1031-1037
45. Westin J, Lagging LM, Spak F, et al. Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. J Viral Hepat 2002;9:235-241
46. DiMartino V, Rufat P, Boyer N, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long term retrospective cohort study. Hepatology 2001;34:1193-1199
47. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C coinfected patients: impact of protease inhibitor therapy. Hepatology 2001;34:283-287
48. Kondili LA, Tosti ME, Szklo M, et al. The relationships of chronic hepatitis and cirrhosis to alcohol intake, hepatitis B and C, and delta virus infection: a case control study in Albania. Epidemiol Infect 1998;121:391-395
49. Nevins CL, Malaty H, Velez ME, Anand BS. Interaction of alcohol and hepatitis C virus infection on severity of liver disease. Dig Dis Sci 1999;44:1236-1242
50. Khan KN, Yatsuhashi H. Effect of alcohol consumption on the progression of hepatitis C virus infection and risk of hepatocellular carcinoma in Japanese patients. Alcohol Alcohol 2000;35:286-295
51. Donato F, Tagger A, Gelatti U, et al. Alcohol and hepatocellular carcinoma: the effect of life time intake of and hepatitis virus infections in men and women. Am J Epidemiol 2002;155:323-331
52. Alemy-Carreau M, Durbec JP, Giordanella J, et al. Lack of interaction between hepatitis C virus and alcohol in the pathogenesis of cirrhosis. A statistical study. J Hepatol 1996; 25:627-632
53. Uchimura Y, Sata M, Kage M, et al. A histopathological study of alcoholics with chronic HCV infection: comparison with chronic hepatitis C and alcoholic liver disease. Liver 1995;15:300-306
54. Cook RT. Alcohol abuse, alcoholism and damage to the immune system— a review. Alcohol Clin Exp Res 1998;22: 1927-1942
55. Jerrells TR, Pruett SB. Immunotoxic effects of ethanol. In Dean JH, Luster MI, Munson AE, Kimber I, eds. Immunotoxicology and Immunopharmacology. New York: Raven Press; 1994:323-347
56. Mufti SI, Prabhala R, Moriguchi S, et al. Functional and numerical alterations induced by ethanol in the cellular immune system. Immunopharmacology 1988;15:85-94
57. Bounds W, Betzing KW, Stewart RM, et al. Social drinking and the immune response: impairment of lymphokine activated killer activity. Am J Med Sci 1994;307:391-395
58. Chiappelli F, Kung M, Lee P, et al. Alcohol modulation of human normal T cell activation, maturation and migration. Alcohol Clin Exp Res 1995;19:539-544
59. Taieb J, Mathurin P, Poynard T, et al. Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease. Lancet 1998; 351:1930-1931
60. Szabo G, Mandrekar P, Dolganiuc A, et al. Reduced alloreactive T cell activation after alcohol intake is due to impaired monocyte accessory cell function and correlates with elevated IL-10, IL-13 and decreased IFN gamma levels. Alcohol Clin Exp Res 2001;25:1766-1772
61. Tsai SL, Liaw YF, Chen MH, et al. Detection of type 2 like T helper cells in hepatitis C virus infection: implications for hepatitis C chronicity. Hepatology 1997;25:449-458
62. Geissler M, Gesien A, Wands JR. Inhibitory effects of chronic ethanol consumption on cellular immune responses to hepatitis C virus core protein are reversed by genetic immunizations augmented with cytokine expressing plasmids. J Immunol 1997;159:5107-5113
63. Cook RT. Cytoplasmic cytokines in the T cells of chronic alcoholics (letter). Alcohol Clin Exp Res 2000;24:241-243
64. Song K, Coleman RA, Albert C, et al. Th1 cytokine response of CD57+ T cell subsets in healthy controls and patients with alcoholic liver disease. Alcohol 2001;24:155-167
65. Saad AJ, Domiati-Saad R, Jerrells TR. Ethanol ingestion increases susceptibility of mice to Listeria monocytogenes. Alcohol Clin Exp Res 1993;17:75-85
66. Sibley D, Jerrells TR. Alcohol consumption by C57BL/6 mice is associated with depletion of lymphoid cells from the gut associated lymphoid tissues and altered resistance to oral infections with Salmonella typhimurium. J Infect Dis 2000; 182:482-489
67. Slukvin I, Boor PJ, Jerrells TR. Inhibition of alcoholic fatty liver and hepatic inflammation with a specific recall immune response in alcohol consuming C57B1/6 mice. Clin Exp Immunol 2001;125:123-133
68. Chisari FV. Cytotoxic T cells and viral hepatitis. J Clin Invest 1997;99:1472-1477
69. Chang KM, Thimme R, Melpolder JJ, et al. Differential CD4+ and CD8+ T cell responsiveness in hepatitis c virus infection. Hepatology 2001;33:267-276
70. Gruener NH, Lechner F, Jung MC, et al. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol 2001;75:5550-5558
71. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001;19:65-91
72. Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 1999;30:595-601
73. Chang KM, Rehermann B, Chisari FV. Immunopathology of hepatitis C. Springer Semin Immunopathol 1997;19: 57-68
74. Pianko S, Patella S, Ostapowicz G, et al. Fas mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection. J Viral Hepat 2001;8:406-413
75. Jerrells TR. Role of activated CD8+ T cells in the initiation and continuation of hepatic damage. Alcohol 2002;27: 47-52
76. Balkow S, Kersten A, Tran TT, et al. Concerted action of the FasL/Fas and perforin/granzyme A and B pathways is mandatory for the development of early viral hepatitis but not for recovery from viral infection. J Virol 2001;75:8781-8791
77. Jerrells TR, Mitchell K, Pavlik J, et al. Influence of ethanol consumption on experimental viral hepatitis. Alcohol Clin Exp Res 2002;26:1734-1746
78. Farinati F, Cardin R, De Maria N, et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995;22:449-456
79. De Maria N, Coloantoni A, Fagiuoli S, et al. Association between reactive oxygen species and disease activity in chronic hepatitis C. Free Radic Biol Med 1996;21:291-295
80. Romero MJ, Bosch-Morell F, Romero B, et al. Serum malondialdehyde: possible use for the clinical managements of chronic hepatitis C patients. Free Radic Biol Med 1998; 25:993-997
81. Barbaro G, Di Lorenzo G, Ribersani M, et al. Serum and hepatic glutathione concentrations in chronic hepatitis C patients related to hepatitis C virus genotype. J Hepatol 1999;30:774-782
82. Kageyama F, Kobayashi Y, Kawasaki T, et al. Successful interferon therapy reverses enhanced hepatic iron accumulation and lipid peroxidation in chronic hepatitis C. Am J Gastroenterol 2000;95:1041-1050
83. Jain SK, Pemberton PW, Smith A, et al. Oxidative stress in chronic hepatitis C: not just a feature of late stage disease. J Hepatol 2002;36:805-811
84. Albano E. Free radicals and alcohol induced liver injury. In: Sherman CDIN, Preedy VR, Watson RR eds. Ethanol and the Liver. London: Taylor and Francis; 2002:153-190
85. Clot P, Tabone M, Arico S, et al. Monitoring oxidative damage in patients with liver cirrhosis and different daily alcohol intake. Gut 1994;35:1637-1643
86. Aleynik SI, Leo MA, Aleynik MK, Lieber CS. Increased circulating products of lipid peroxidation in patients with alcoholic liver disease. Alcohol Clin Exp Res 1998;22:192-196
87. Meager EA, Barry OP, Burke A, et al. Alcohol induced generation of lipid peroxidation products in humans. J Clin Invest 1999;104:805-813
88. Nimela O, Parkkila S, Britton RS, et al. Hepatic lipid peroxidation in hereditary hemochromatosis and alcoholic liver disease. J Lab Clin Med 1999;133:451-460
89. Hoek JB, Cahill A, Pastorino JG. Alcohol and mitochondria: a dysfunctional relationship. Gastroenterology 2002;122: 2049-2063
90. Letteron P, Fromenty B, Terris B, et al. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 1996;24:200-208
91. Letteron P, Duchatelle V, Berson A, et al. Increased ethane exhalation, an in vivo index of lipid peroxidation, in alcohol abusers. Gut 1993;34:409-414
92. Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral related steatosis. FASEB J 2002;16:185-194
93. Okuda M, Li K, Beard MR, et al. Mitochondrial injury, oxidative stress and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122:366-375
94. Moriya K, Nakagawa K, Santa T, et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus associated hepatocarcinogenesis. Cancer Res 2001; 61:4365-4370
95. Rigamonti C, Mottaran E, Reale E, et al. Moderate alcohol consumption increases oxidative stress in patients with chronic hepatitis C. Hepatology 2003;38:42-49
96. Perlemuter G, Letteron P, Carnot F, et al. Alcohol and hepatitis C virus core protein additively increase lipid peroxidation and synergistically trigger hepatic cytokine expression in a transgenic mouse model. J Hepatol 2003;39:1020-1027
97. Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 1996;313:17-29
98. Girotti AW. Lipid hydroperoxide generation, turnover and effector action in biological systems. J Lipid Res 1998;39: 1529-1542
99. Schmid RM, Adler G. NF-kappaB/rel/IkappaB: implications in gastrointestinal diseases. Gastroenterology 2000; 118:1208-1228
100. Baeuerle PA. Proinflammatory signaling: last pieces in the NF-kappaB puzzle? Curr Biol 1998;8:R19-R22
101. Cressman DE, Greenbaum LE, Haber BA, et al. Rapid activation of post hepatectomy factor/nuclear factor kappa B in hepatocytes, a primary response in the regenerating liver. J Biol Chem 1994;269:30429-30435
102. Tai DI, Tsai SL, Chen YM, et al. Activation of nuclear factor kappaB in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis. Hepatology 2000; 31:656-664
103. Kim WH, Hong F, Jaruga B, et al. Additive activation of hepatic NF-kappa B by ethanol and hepatitis B protein X (HBX) or HCV core protein: involvement of TNF-alpha receptor 1-independent and -dependent mechanisms. FASEB J 2001;15:2551-2553
104. Gao B. Integration of alcohol and hepatitis viral proteins: implication in synergistic effect of alcohol drinking and viral hepatitis on liver injury. Alcohol 2002;26:69-72
105. Schiff ER. Hepatitis C and alcohol. Hepatology 1997; 26(Suppl 1):39S-42S
106. Mendenhaall CL, Seef L, Diehl AM, et al. Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: their prevalence. Hepatology 1991;14:581-589
107. Pares A, Barrera JM, Caballeria J, et al. Hepatitis virus antibodies in chronic alcoholic patients: association with severity of liver injury. Hepatology 1990;12:1295-1299
108. Fong TL, Kanel GC, Conrad A, et al. Clinical significance of concomitant hepatitis C infection in patients with alcoholic liver disease. Hepatology 1994;19:554-557
109. Rosman AS, Paronetto F, Galvin K, et al. Hepatitis C virus antibody in alcoholic patients. Association with the presence of portal and/or lobular hepatitis. Arch Intern Med 1993; 153:965-969
110. Loguercio C, Di Pierro M, Di Marino MP, et al. Drinking habits of subjects with hepatitis C virus related chronic liver disease: prevalence and effect on clinical, virological and pathological aspects. Alcohol Alcohol 2000;35:296-301
111. Cromie SL, Jenkins PJ, Bowden DS, et al. Chronic hepatitis C: effect of alcohol on hepatic activity and viral titer. J Hepatol 1996;25:821-826
112. Anand BS, Velez M. Influence of chronic alcohol abuse on hepatitis C virus replication. Dig Dis 2000;18:168-171
113. Fanning L, Kenny E, Sheehan M, et al. Viral load and clinicopathologic features of chronic hepatitis C in a homogenous patient population. Hepatology 1999;29:904-907
114. Lau YJ, Davis GL, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501-1504
115. Martniot-Peignoux M, Marcellin P, Gournay J, et al. Detection and quantitation of serum HCV RNA by branched DNA amplification in anti-HCV positive blood donors. J Hepatol 1994;20:676-678
116. Romero-Gomez M, Grande L, Nogales MC, et al. Intrahepatic hepatitis C virus replication is increased in patients with regular alcohol consumption. Dig Liver Dis 2001;33: 698-702
117. Haydon GH, Jarvis LM, Blair CS, et al. Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection. Gut 1998;42:570-575
118. Sawada M, Takada A, Takase S, et al. Effects of alcohol on the replication of hepatitis C virus. Alcohol Alcohol 1993;28: 85-90
119. Zhang T, Li Y, Lai JP, et al. Alcohol potentiates hepatitis C virus replicon expression. Hepatology 2003;38:57-65
120. Sherman KE, Rouster SD, Mendenhall C, et al. Hepatitis C RNA quasispecies complexity in patients with alcoholic liver disease. Hepatology 1999;30:265-270
121. Takahashi K, Takahashi T, Takahashi S, et al. Difference in quasispecies of the hypervariable region 1 of hepatitis C virus between alcoholic and non alcoholic patients. J Gastroenterol Hepatol 2001;16:416-423
122. Izumi N, Enomoto N, Uchihara M, et al. Hepatic iron contents and response to interferon alpha in patients with chronic hepatitis C. Dig Dis Sci 1996;41:989-994
123. Piperno A, Vergani A, Malosio I, et al. Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations. Hepatology 1998;28:1105-1109
124. Smith BC, Gorve J, Guzail MA, et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998;27:1695-1699
125. Patel T, Roberts LR, Jones BA, et al. Dysregulation of apoptosis as a mechanism of liver disease: an overview. Semin Liver Dis 1998;18:105-114
126. Pianko S, Patella S, Sievert W. Alcohol consumption induces hepatocyte apoptosis in patients with chronic hepatitis C infection. J Gastroenterol Hepatol 2000;15: 798-805
127. Zhu N, Khoshan A, Schneider R, et al. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF induced apoptosis. J Virol 1998;72:3691-3697
128. Scheuer PJ, Ashrafzadeh P, Sherlock S, et al. The pathology of hepatitis C. Hepatology 1992;15:567-571
129. Lefkowitch JH, Schiff ER, Davis GL, et al. Pathological diagnosis of chronic hepatitis C: A multicenter comparative study with chronic hepatitis B. Gastroenterology 1993;104: 595-603
130. Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: A comparative analysis. Hepatology 1992;15:572-577
131. Czaja AJ, Carpenter HA, Santrach PJ, et al. Host and disease specific factors affecting steatosis in chronic hepatitis C. J Hepatol 1998;29:198-206
132. Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999;29:1215-1219
133. Fiore G, Fera G, Napoli N, et al. Liver steatosis and chronic hepatitis C: a spurious association? Eur J Gastroenterol Hepatol 1996;8:125-129
134. Poupon R, Serfaty S, Amorim M, et al. Combination of steatosis and alcohol intake is the main determinant of fibrosis progression in patients with hepatitis C. Hepatology 1999;30(suppl):406A
135. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-1364
136. Serfaty L, Poujol-Robert A, Carbonell N, et al. Effect of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hepatitis C. Am J Gastroenterol 2002;97:1807-1812
137. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-497
138. Romeo R, Rumi MG, Donato MF, et al. Hepatitis C is more severe in drug users with human immunodeficiency virus infection. J Viral Hepat 2000;7:297-301
139. Harris HE, Ramsay ME, Andrews N, Eldridge KP. Clinical course of hepatitis C virus during the first decade of infection: cohort study. BMJ 2002;324:450-453
140. Kim WR, Gross JB Jr, Poterucha JJ, et al. Outcome of hospital care of liver disease associated with hepatitis C in the United States. Hepatology 2001;33:201-206
141. Bruix J, Barrera JM, Calvet X, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989;2:1004-1006
142. Nalpas B, Feitesol M, Brechot C, et al. Alcohol, hepatotropic viruses and hepatocellular carcinoma. Alcohol Clin Exp Res 1995;19:1089-1095
143. Miyakawa H, Sato C, Izumi N, et al. Hepatitis C virus infection in alcoholic liver cirrhosis in Japan: Its contribution to the development of hepatocellular carcinoma. Alcohol Alcohol 1993;1A(Suppl):85-90
144. Takase S, Tsutsumi M, Kawahara H, et al. The alcohol altered liver membrane antibody and hepatitis C virus infection in the progression of alcoholic liver disease. Hepatology 1993;17:9-13
145. Yamauchi M, Nakahara M, Maezawa Y, et al. Prevalence of hepatocellular carcinoma in patients with alcoholic cirrhosis and prior exposure to hepatitis C. Am J Gastroenterol 1993; 88:39-43
146. Donato F, Tagger A, Chiesa R, et al. Hepatitis B and C virus infection, alcohol drinking and hepatocellular carcinoma: a case control study in Italy. Brescia HCC study. Hepatology 1997;26:579-584
147. Chiba T, Matsuzaki Y, Abei M, et al. Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis. J Gastroenterol 1996;31: 552-558
148. Simonetti RG, Camma C, Fiorello F, et al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case control study. Ann Intern Med 1992;116:97-102
149. Miyakawa H, Izumi N, Marumo F, Sato C. Roles of alcohol, hepatitis virus infection and gender in the development of hepatocellular carcinoma in patients with liver cirrhosis. Alcohol Clin Exp Res 1996;20(Suppl 1):91A-94A
150. Ikeda K, Saitoch S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis:A prospective observation of 2215 patients. J Hepatol 1998;28:930-938
151. Kuwana K, Ichida T, Kamimura T, et al. Risk factors and the effect of interferon therapy in the development of hepatocellular carcinoma. J Gastroenterol Hepatol 1997;12: 149-155
152. Aizawa Y, Shibamoto Y, Takagi I. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. Cancer 2000;89:53-59
153. Matsuda Y, Amuro Y, Higashino K, et al. Relation between markers for viral hepatitis and clinical features of Japanese patients with hepatocellular carcinoma: possible role of alcohol in promoting carcinogenesis. Hepatogastroenterology 1995;42:151-154
154. Noda K, Yoshira H, Suzuki K, et al. Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma: its relationship to alcoholic drinking and the age of transfusion. Alcohol Clin Exp Res 1996;20:95A-100A
155. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002;36(Suppl 1):S74-S83
156. Hassan MM, Hwang LU, Hatten CJ, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002;36:1206-1213
157. Shimauchi Y, Tanaka M, Koga K, et al. Clinical characteristics of patients in their 40s with HCV antibody positive hepatocellular carcinoma. Alcohol Clin Exp Res 2000; 24(Suppl 4):64S-67S
158. Yamanaka T, Shiraki K, Nakazaawa S, et al. Impact of hepatitis B and C virus infection on the clinical prognosis of alcoholic liver cirrhosis. Anticancer Res 2001;21:2937-2940
159. Kubo S, Kinoshita H, Hirohashi K, et al. High malignancy of hepatocellular carcinoma in alcoholic patients with hepatitis C virus. Surgery 1997;121:425-429
160. Okada S, Ishii H, Nose H, et al. Effect of heavy alcohol intake on long term results after curative resection of hepatitis C virus related hepatocellular carcinoma. Jpn J Cancer Res 1996;87:867-873
161. Bhattacharya R, Shuhart MC. Hepatitis C and alcohol. Interactions, outcomes and implications. J Clin Gastroenterol 2003;36:242-252
162. Inoue H, Seitz HK. Viruses and alcohol in the pathogenesis of primary hepatic carcinoma. Eur J Cancer Prev 2001;10: 107-110
163. Peters MG, Terrault NA. Alcohol use and hepatitis C. Hepatology 2002;36(Suppl 1):S220-S225
164. Schiff ER. The alcoholic patient with hepatitis C virus infection. Am J Med 1999;107:95S-99S
165. Jamal MM, Morgan TR. Liver disease in alcohol and hepatitis C. Best Pract Res Clin Gastroenterol 2003;17:649-662
166. Okazaki M, Yoshihara H, Suzuki K, et al. Efficacy of interferon therapy inpatients with chronic hepatitis C. Comparison between drinkers and non drinkers. Scand J Gastroenterol 1994;29:1039-1043
167. Ohnishi K, Matsuo S, Matsutani K, et al. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996;91:1374-1379
168. Mochida S, Ohnishi K, Matsuo S, et al. Effect of alcohol intake on the efficacy of interferon therapy in patients with chronic hepatitis C as evaluated by multivariate logistic regression analysis. Alcohol Clin Exp Res 1996;20:371A-377A
169. Tabone M, Sidoli L, Laudi C, et al. Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy. J Viral Hepat 2002;9:288-294
170. Koizumi K, Enomoto N, Kurosaki M, et al. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology 1995;22:30-35
171. Zylberg H, Fontaine H, Thepot V, et al. Triggering of acute alcoholic hepatitis by alpha interferon therapy. J Hepatol 1999;30:722-725
172. Van Thiel DH, Friedlander L, Fagiuoli S, et al. Response to interferon alpha is influenced by the iron content of the liver. J Hepatol 1994;20:410-415
173. Olynyk JK, Reddy KR, Di Bisceglie AM, et al. Hepatic iron concentration as a predictor of response to interferon alpha therapy in chronic hepatitis C. Gastroenterology 1995;108: 1104-1109
174. Vento S, Cainelli F. Does hepatitis C virus cause severe liver disease only in people who drink alcohol? Lancet Infect Dis 2002;2:303-309
175. Regev A, Jeffers LJ. Hepatitis C and alcohol. Alcohol Clin Exp Res 1999;23:1543-1551

Reprint Address

Eugene R. Schiff, M.D., Center for Liver Diseases, University of Miami, 1500 NW 12th Avenue, Suite 1101, Miami, FL 33136. E-mail: [e-mail]
Abbreviation Notes

CTL = cytotoxic T-lymphocyte; HCC = hepatocellular carcinoma; HCV = hepatitis C virus; HSC = hepatic stellate cells; IFN = interferon; IL = interleukin; IVDU = intravenous drug use; LDAI = lifetime daily alcohol intake; NF-κβ = nuclear transcription factor-kappa β; ROS = reactive oxygen species; Th = T helper; TNF = tumor necrosis factor; TGF-β = transforming growth factor beta


Kamran Safdar, M.D.,1 and Eugene R. Schiff, M.D.1,2

1Center for Liver Diseases, Division of Hepatology, Department of Medicine, University of Miami, Miami, Florida; 2Professor of Medicine, University of Miami, Miami, Florida

http://www.medscape.com/viewarticle/488940_print